MoneyWorks4Me

Biocon sells stake in Syngene International

10 Dec 2024 Evaluate

Biocon has sold 80,00,000 equity shares of Syngene International (Syngene) in open market through block deal mechanism on December 10, 2024. Post this transaction, the shareholding of the Company in Syngene shall stand at 52.46%. 

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..